Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

@article{Patel2007EffectsOA,
  title={Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial},
  author={Anushka Patel},
  journal={The Lancet},
  year={2007},
  volume={370},
  pages={829-840}
}
BACKGROUND Blood pressure is an important determinant of the risks of macrovascular and microvascular complications of type 2 diabetes, and guidelines recommend intensive lowering of blood pressure for diabetic patients with hypertension. We assessed the effects of the routine administration of an angiotensin converting enzyme (ACE) inhibitor-diuretic combination on serious vascular events in patients with diabetes, irrespective of initial blood pressure levels or the use of other blood… Expand
Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence
TLDR
Routine treatment with the fixed combination of perindopril and indapamide was well tolerated and reduced the risk of death and major vascular events, regardless of the initial blood pressure level or concomitant treatments received. Expand
Reducing cardiovascular risk in diabetes: insights from the ADVANCE study
TLDR
Routine administration of a fixed combination of perindopril and indapamide to patients with type 2 diabetes and with a good controlled blood pressure was well tolerated and reduced the risks of major vascular events, including death, but it remains the doubt if these results have been obtained because of the better pressure control or are specific of this preconstructed association. Expand
Management of high blood pressure in type 2 diabetes: perindopril/indapamide fixed-dose combination and the ADVANCE trial
  • L. Ghiadoni
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2010
TLDR
This review focuses on the benefits of the fixed-dose combination of perindopril and indapamide on cardiovascular and renal end points in the ADVANCE trial, which provides a new, simple and pragmatic treatment algorithm that maximizes clinical benefits and is suitable for all type 2 diabetic patients. Expand
Effects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus: Results From the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) Trial
TLDR
The combination of perindopril and indapamide with CCBs seems to provide further protection against mortality in patients with type 2 diabetes mellitus. Expand
Trials That Matter: The Effect of a Fixed-Dose Combination of an Angiotensin-Converting Enzyme Inhibitor and a Diuretic on the Complications of Type 2 Diabetes
TLDR
The ADVANCE trial was an empirical test of principle for the blood pressurelowering component of a future combination polypill in this population of patients with type 2 diabetes, and showed that a fixed, low-dose combination of perindopril and indapamide added to standard background antihypertensive treatment could safely reduce both microvascular and macrovascular complications. Expand
Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial.
TLDR
It is concluded that a fixed dose combination of perindopril and indapamide should be recommended for all patients with type 2 diabetes, irrespective of their existing blood pressure, based on data from the ADVANCE trial. Expand
Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes
TLDR
The effects of routine blood pressure lowering and intensive glucose control were independent of one another, and when combined, they produced additional reductions in clinically relevant outcomes. Expand
Routine blood pressure lowering and intensive glucose control in patients with Type 2 diabetes: the ADVANCE trial
TLDR
Intensive glucose control was not associated with a significant reduction in macrovascular events; however, unlike reports from the recently reported Action to Control Cardiovascular Risk in Diabetes (ACCORD), there was no evidence of any increase in all-cause mortality or cardiovascular death with more intensive glucose control. Expand
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes
TLDR
In the large diabetic subgroup in the blood pressure-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial, the benefits of amlodipine-based treatment, compared with atenolol- based treatment, on the incidence of total cardiovascular events and procedures was significant and similar to that observed in the total trial population. Expand
Vascular legacy beyond blood pressure control: benefits of perindopril/indapamide combination in hypertensive patients with diabetes
TLDR
Treatment with perindopril/indapamide has microvascular and macrovascular effects that extend beyond blood pressure lowering and that this treatment might confer a long-lasting beneficial vascular legacy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy
TLDR
Ramipril was beneficial for cardiovascular events and overt nephropathy in people with diabetes and the cardiovascular benefit was greater than that attributable to the decrease in blood pressure. Expand
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri
TLDR
The amlodipine-based regimen prevented more major cardiovascular events and induced less diabetes than the atenolol- based regimen, and these effects might not be entirely explained by better control of blood pressure. Expand
Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression.
TLDR
On the basis of available RCT evidence, ACEi and ARB are the only agents with proven renal benefit in patients who have diabetes with no nephropathy and the only agent with proven survival benefit in Patients who haveabetes with nephrolysis. Expand
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
TLDR
Tight blood pressure control in patients with hypertension and type 2 diabetes achieves a clinically important reduction in the risk of deaths related to diabetes, complications related to Diabetes, progression of diabetic retinopathy, and deterioration in visual acuity. Expand
Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.
TLDR
These overviews showed that the short- to-medium-term effects on major cardiovascular events of the BP-lowering regimens studied were broadly comparable for patients with and without diabetes. Expand
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
TLDR
The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared. Expand
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
TLDR
There were no significant differences in total major cardiovascular events between regimens based on ACE inhibitors, calcium antagonists, or diuretics or beta blockers, although ACE-inhibitor-based regimens reduced blood pressure less. Expand
Rationale and design of the AdRem study: evaluating the effects of blood pressure lowering and intensive glucose control on vascular retinal disorders in patients with type 2 diabetes mellitus.
TLDR
The AdRem study is designed to provide reliable evidence on the effects of intensive glucose control and blood pressure lowering on both diabetic retinopathy and abnormalities of retinal vasculature in patients with type 2 diabetes mellitus. Expand
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.
TLDR
Attempts to improve glycemic control reduce the incidence of macrovascular events both in type 1 and type 2 DM, in absolute terms, although effects on specific manifestations of macroVascular disease differ. Expand
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials
TLDR
Results showing these benefits in intermediate-risk patients complement existing evidence of similar benefit in higher- risk patients with LVSD or heart failure and should be considered in all patients with atherosclerosis. Expand
...
1
2
3
4
...